 |
4 Diseases |  |
6 Trials |
|
6 Trials |  |
725 News |  |
| «123456789 |
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment closed: A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics (clinicaltrials.gov) - Dec 13, 2013
P4, N=617, Active, not recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Recruiting --> Active, not recruiting
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment closed, Head-to-Head: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Nov 24, 2013
P3, N=1431, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion, Adherence: A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate (clinicaltrials.gov) - Nov 24, 2013
P4, N=154, Completed, Sponsor: Janssen Korea, Ltd., Korea
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder (clinicaltrials.gov) - Oct 30, 2013
P3, N=667, Completed, Sponsor: Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P1 trial: A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia (clinicaltrials.gov) - Sep 9, 2013
P1, N=76, Completed, Sponsor: Janssen Pharmaceutical K.K.
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia (clinicaltrials.gov) - Sep 9, 2013
P1, N=76, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial initiation date: A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients (clinicaltrials.gov) - Sep 8, 2013
P4, N=3000, Recruiting, Sponsor: Janssen Korea, Ltd., Korea
Not yet recruiting --> Completed Initiation date: May 2011 --> Oct 2012
- |||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment open: A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients (clinicaltrials.gov) - Sep 8, 2013
P4, N=3000, Recruiting, Sponsor: Janssen Korea, Ltd., Korea
Initiation date: May 2011 --> Oct 2012 Active, not recruiting --> Recruiting
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment change: Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital (clinicaltrials.gov) - Jul 3, 2013
P4, N=0, Withdrawn, Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Active, not recruiting --> Recruiting N=1000 --> 0
- ||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia (clinicaltrials.gov) - Jun 26, 2013
P3, N=546, Completed, Sponsor: Johnson & Johnson Pte Ltd
N=1000 --> 0 Active, not recruiting --> Completed
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment open: Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia (clinicaltrials.gov) - Jun 8, 2013
P4, N=170, Recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: The Effect of Paliperidone Palmitate in Schizophrenia (clinicaltrials.gov) - May 21, 2013
P4, N=30, Recruiting, Sponsor: Seoul National University Hospital
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial initiation date: Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study (clinicaltrials.gov) - Apr 29, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Maryland
Not yet recruiting --> Recruiting Initiation date: Jan 2013 --> Jan 2014
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion, Monotherapy: PROSIPAL: Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics (clinicaltrials.gov) - Apr 3, 2013
P3, N=769, Completed, Sponsor: Janssen-Cilag International NV
Initiation date: Jan 2013 --> Jan 2014 Active, not recruiting --> Completed
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients (clinicaltrials.gov) - Mar 26, 2013
P4, N=3000, Recruiting, Sponsor: Janssen Korea, Ltd., Korea
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment change: A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia (clinicaltrials.gov) - Mar 3, 2013
P2, N=56, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed N=73 --> 56
- |||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
Enrollment open: Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia (clinicaltrials.gov) - Feb 28, 2013
P3, N=286, Recruiting, Sponsor: H. Lundbeck A/S
N=73 --> 56 Not yet recruiting --> Recruiting
- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
New P3 trial: Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia (clinicaltrials.gov) - Feb 18, 2013
P3, N=286, Recruiting, Sponsor: H. Lundbeck A/S
- ||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia (clinicaltrials.gov) - Dec 12, 2012
P3, N=201, Completed, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Risperdal Consta (risperidone depot formulation) / J&J
Clinical: Switching From Consta® to Sustenna® in Patients With Schizophrenia (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=50, Recruiting, Sponsor: Seoul National University Hospital
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics (clinicaltrials.gov) - Sep 12, 2012
P4, N=617, Active, not recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial, Adherence: A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate (clinicaltrials.gov) - Sep 6, 2012
P4, N=154, Completed, Sponsor: Janssen Korea, Ltd., Korea
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment closed: ACLAIMS: A Comparison of Long-acting Injectable Medications for Schizophrenia (clinicaltrials.gov) - Sep 5, 2012
P4, N=360, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia (clinicaltrials.gov) - Jun 17, 2012
P3, N=323, Completed, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial initiation date: Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia (clinicaltrials.gov) - Jun 13, 2012
P4, N=50, Not yet recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Aug 2012
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P2 trial: A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia (clinicaltrials.gov) - May 23, 2012
P2, N=56, Completed, Sponsor: Janssen Pharmaceutical K.K.
- |||| risperidone / Generic mfg.
Enrollment open: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia (clinicaltrials.gov) - Mar 26, 2012
P2, N=60, Recruiting, Sponsor: PharmaNeuroBoost N.V.
Initiation date: Oct 2011 --> Aug 2012 Not yet recruiting --> Recruiting
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia (clinicaltrials.gov) - Feb 5, 2012
P4, N=212, Completed, Sponsor: Johnson & Johnson Pte Ltd
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P3 trial, Head-to-Head: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Jan 22, 2012
P3, N=1431, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia (clinicaltrials.gov) - Oct 20, 2011
P4, N=50, Not yet recruiting, Sponsor: University of California, Los Angeles
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia (clinicaltrials.gov) - Oct 12, 2011
P4, N=170, Recruiting, Sponsor: University of California, Los Angeles
- ||||| risperidone / Generic mfg.
New P2 trial: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia (clinicaltrials.gov) - Oct 10, 2011
P2, N=60, Recruiting, Sponsor: PharmaNeuroBoost N.V.